Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Prostate screening halves cancer mortality

  • Comment

Prostate cancer screening reduces mortality risk by almost half, according to a Swedish study.

Researchers studied 10,000 men, aged 50 to 65 years, to assess the merits of prostate-specific antigen screening.

Prostate cancer was diagnosed in 1,138 men in a group who underwent PSA screening and 718 in a control group.  During 14 years of follow-up, prostate cancer mortality in the screening group was almost half that of the control group. The findings were published online in the The Lancet Oncology.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.